Magneclo (Magnesium Chloride Hexahydrate)

After IV administration, magnesium chloride hexahydrate releases magnesium ions that serve as cofactors for many enzymatic processes, stabilize ATP, regulate calcium channels, and help maintain normal nerve, muscle, and cardiac function, thereby restoring electrolyte balance.

The dose of Magneclo is determined by the prescribing clinician based on the patient’s serum magnesium level, renal function, and clinical condition. The prescriber sets the infusion rate and total amount required for each individual case.

The pregnancy category for magnesium chloride hexahydrate is unknown. Use in pregnancy or while breastfeeding should only occur when the potential benefit justifies any possible risk, and it must be decided by the treating physician.

To order Magneclo, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Magneclo provides magnesium chloride hexahydrate in a sterile injectable solution, offering rapid bioavailability compared with oral magnesium salts. It is preferred when immediate correction of magnesium levels is required, whereas oral preparations are used for maintenance therapy.

Magneclo should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use and discard any solution that appears discolored or contains particles.

Magneclo is administered intravenously by slow infusion under the supervision of qualified healthcare personnel. The infusion rate and total dose are individualized according to the patient’s clinical status and laboratory results.

Serious risks include hypermagnesemia, which can cause cardiac arrhythmias, severe hypotension, respiratory depression, and in rare cases anaphylactic reactions. Continuous monitoring of vital signs and serum magnesium levels is essential during therapy.

Magneclo should be avoided in patients with known hypersensitivity to magnesium chloride, severe renal failure where magnesium clearance is impaired, and in individuals with existing hypermagnesemia. Clinicians must assess each patient’s suitability before initiating therapy.